![Thomas Sabia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Thomas Sabia formerly worked at Quince Therapeutics SpA, as Chief Commercial Officer from 2022 to 2023 and Quince Therapeutics, Inc., as Chief Commercial Officer from 2022 to 2025.
Mr. Sabia received his undergraduate degree and Masters Business Admin degree from Salisbury State University.
Former positions of Thomas Sabia
| Companies | Position | End |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | Corporate Officer/Principal | 28/02/2025 |
EryDel SpA
 EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Corporate Officer/Principal | 01/10/2023 |
Training of Thomas Sabia
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
5
1st degree connections
3
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Salisbury State University
 Salisbury State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EryDel SpA
EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Health Technology |
Quince Therapeutics, Inc.
 Quince Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops drugs for the treatment of central nervous system disorders and Alzheimer’s diseases | Health Technology |
- Stock Market
- Insiders
- Thomas Sabia
